NIH Human Embryonic Stem Cell Registry – Research Using …

CHB-1 (see details) 0001 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-2 (see details) 0002 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-3 (see details) 0003 On Hold ** George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-4 (see details) 0004 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-5 (see details) 0005 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-6 (see details) 0006 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-8 (see details) 0007 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-9 (see details) 0008 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-10 (see details) 0009 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-11 (see details) 0010 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 CHB-12 (see details) 0011 George Q. Daley, M.D., Ph.D. Children's Hospital Corporation 12/02/2009 RUES1 (see details) 0012 The Rockefeller University, Ali Brivanlou The Rockefeller University 12/02/2009 RUES2 (see details) 0013 The Rockefeller University, Ali Brivanlou The Rockefeller University 12/02/2009 HUES 1 (see details) 0014 HSCI iPS Core Harvard University 12/14/2009 HUES 2 (see details) 0015 HSCI iPS Core Harvard University 12/14/2009 HUES 3 (see details) 0016 HSCI iPS Core Harvard University 12/14/2009 HUES 4 (see details) 0017 HSCI iPS Core Harvard University 12/14/2009 HUES 5 (see details) 0018 HSCI iPS Core Harvard University 12/14/2009 HUES 6 (see details) 0019 HSCI iPS Core Harvard University 12/14/2009 HUES 7 (see details) 0020 HSCI iPS Core Harvard University 12/14/2009 HUES 8 (see details) 0021 HSCI iPS Core Harvard University 12/14/2009 HUES 9 (see details) 0022 HSCI iPS Core Harvard University 12/14/2009 HUES 10 (see details) 0023 HSCI iPS Core Harvard University 12/14/2009 HUES 11 (see details) 0024 HSCI iPS Core Harvard University 12/14/2009 HUES 12 (see details) 0025 HSCI iPS Core Harvard University 12/14/2009 HUES 13 (see details) 0026 HSCI iPS Core Harvard University 12/14/2009 HUES 14 (see details) 0027 HSCI iPS Core Harvard University 12/14/2009 HUES 15 (see details) 0028 HSCI iPS Core Harvard University 12/14/2009 HUES 16 (see details) 0029 HSCI iPS Core Harvard University 12/14/2009 HUES 17 (see details) 0030 HSCI iPS Core Harvard University 12/14/2009 HUES 18 (see details) 0031 HSCI iPS Core Harvard University 12/14/2009 HUES 19 (see details) 0032 HSCI iPS Core Harvard University 12/14/2009 HUES 20 (see details) 0033 HSCI iPS Core Harvard University 12/14/2009 HUES 21 (see details) 0034 HSCI iPS Core Harvard University 12/14/2009 HUES 22 (see details) 0035 HSCI iPS Core Harvard University 12/14/2009 HUES 23 (see details) 0036 HSCI iPS Core Harvard University 12/14/2009 HUES 24 (see details) 0037 HSCI iPS Core Harvard University 12/14/2009 HUES 26 (see details) 0038 HSCI iPS Core Harvard University 12/14/2009 HUES 27 (see details) 0039 HSCI iPS Core Harvard University 12/14/2009 HUES 28 (see details) 0040 HSCI iPS Core Harvard University 12/14/2009 CyT49 (see details) 0041 ViaCyte, Inc. 01/19/2010 RUES3 (see details) 0042 The Rockefeller University, Ali Brivanlou The Rockefeller University 01/19/2010 WA01 (H1) (see details) 0043 WiCell Research Institute WiCell Research Institute 01/29/2010 UCSF4 (see details) 0044 Susan Fisher University of California San Francisco 03/12/2010 NYUES1 (see details) 0045 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES2 (see details) 0046 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES3 (see details) 0047 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES4 (see details) 0048 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES5 (see details) 0049 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES6 (see details) 0050 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 NYUES7 (see details) 0051 Christoph Hansis, MD, PhD New York University School of Medicine 03/29/2010 MFS5; disease-specific mutation (see details) 0052 Eric Chiao Stanford University 04/27/2010 HUES 48 (see details) 0053 HSCI iPS Core Harvard University 04/27/2010 HUES 49 (see details) 0054 HSCI iPS Core Harvard University 04/27/2010 HUES 53 (see details) 0055 HSCI iPS Core Harvard University 04/27/2010 HUES 65 (see details) 0056 HSCI iPS Core Harvard University 04/27/2010 HUES 66 (see details) 0057 HSCI iPS Core Harvard University 04/27/2010 UCLA 1 (see details) 0058 Steven Peckman University of California, Los Angeles 04/27/2010 UCLA 2 (see details) 0059 Steven Peckman University of California, Los Angeles 04/27/2010 UCLA 3 (see details) 0060 Steven Peckman University of California, Los Angeles 04/27/2010 WA07 (H7) (see details) 0061 WiCell Research Institute WiCell Research Institute 04/27/2010 WA09 (H9) (see details) 0062 WiCell Research Institute WiCell Research Institute 04/27/2010 WA13 (H13) (see details) 0063 WiCell Research Institute WiCell Research Institute 04/27/2010 WA14 (H14) (see details) 0064 WiCell Research Institute WiCell Research Institute 04/27/2010 HUES 62 (see details) 0065 HSCI iPS Core Harvard University 06/03/2010 HUES 63 (see details) 0066 HSCI iPS Core Harvard University 06/03/2010 HUES 64 (see details) 0067 HSCI iPS Core Harvard University 06/03/2010 CT1 (see details) 0068 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010 CT2 (see details) 0069 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010 CT3 (see details) 0070 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010 CT4 (see details) 0071 University of Connecticut Stem Cell Core UNIVERSITY OF CONNECTICUT SCH OF MED/DNT 06/21/2010 MA135 (see details) 0072 Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. 06/21/2010 Endeavour-2 (see details) 0073 Kuldip Sidhu Stem Cell Laboratory, Faculty of medicine, University of New South Wales 06/21/2010 WIBR1 (see details) 0074 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 06/21/2010 WIBR2 (see details) 0075 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 06/21/2010 HUES 45 (see details) 0076 HSCI iPS Core Harvard University 09/28/2010 Shef 3 (see details) 0077 Centre for Stem Cell Biology University of Sheffield 11/17/2010 Shef 6 (see details) 0078 Centre for Stem Cell Biology University of Sheffield 11/17/2010 WIBR3 (see details) 0079 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010 WIBR4 (see details) 0080 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010 WIBR5 (see details) 0081 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010 WIBR6 (see details) 0082 Whitehead Institute for Biomedical Research/Maya Mitalipova Whitehead Institute for Biomedical Research 11/17/2010 BJNhem19 (see details) 0083 Jawaharlal Nehru Centre for Advanced Scientific Research Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010 BJNhem20 (see details) 0084 Jawaharlal Nehru Centre for Advanced Scientific Research Jawaharlal Nehru Centre for Advanced Scientific Research 12/17/2010 SA001 (see details) 0085 Cellartis AB Cellartis AB 12/17/2010 SA002; abnormal karyotype (see details) 0086 Cellartis AB Cellartis AB 12/17/2010 UCLA 4 (see details) 0087 Steven Peckman University of California Los Angeles 02/03/2011 UCLA 5 (see details) 0088 Steven Peckman University of California Los Angeles 02/03/2011 UCLA 6 (see details) 0089 Steven Peckman University of California Los Angeles 02/03/2011 HUES PGD 13; disease-specific mutation (see details) 0090 Eggan Lab Harvard University 03/15/2011 HUES PGD 3; disease-specific mutation (see details) 0091 Eggan Lab Harvard University 03/15/2011 ESI-014 (see details) 0092 BioTime, Inc. 06/02/2011 ESI-017 (see details) 0093 BioTime, Inc. BioTime, Inc. 06/02/2011 HUES PGD 11; disease-specific mutation (see details) 0094 Eggan Lab Harvard University 06/07/2011 HUES PGD 12; disease-specific mutation (see details) 0095 Eggan Lab Harvard University 06/07/2011 WA15 (see details) 0096 WiCell Research Institute WiCell Research Institute 06/09/2011 WA16; disease-specific mutation/abnormal karyotype (see details) 0097 WiCell Research Institute WiCell Research Institute 06/09/2011 WA17 (see details) 0098 WiCell Research Institute WiCell Research Institute 06/09/2011 WA18 (see details) 0099 WiCell Research Institute WiCell Research Institute 06/09/2011 WA19 (see details) 0100 WiCell Research Institute WiCell Research Institute 06/09/2011 WA20 (see details) 0101 WiCell Research Institute WiCell Research Institute 06/09/2011 WA21 (see details) 0102 WiCell Research Institute WiCell Research Institute 06/09/2011 WA22 (see details) 0103 WiCell Research Institute WiCell Research Institute 06/09/2011 WA23 (see details) 0104 WiCell Research Institute WiCell Research Institute 06/09/2011 WA24 (see details) 0105 WiCell Research Institute WiCell Research Institute 06/09/2011 CSES2 (see details) 0106 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES4 (see details) 0107 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES7 (see details) 0108 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES8; abnormal karyotype (see details) 0109 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES11; abnormal karyotype (see details) 0110 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES12; abnormal karyotype (see details) 0111 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES13; abnormal karyotype (see details) 0112 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES14; abnormal karyotype (see details) 0113 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES15 (see details) 0114 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES17 (see details) 0115 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES19 (see details) 0116 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES20; abnormal karyotype (see details) 0117 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES21; abnormal karyotype (see details) 0118 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES22; abnormal karyotype (see details) 0119 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES23; abnormal karyotype (see details) 0120 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES24; abnormal karyotype (see details) 0121 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 CSES25 (see details) 0122 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 06/10/2011 HAD-C 100 (see details) 0123 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011 HAD-C 102 (see details) 0124 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011 HAD-C 106 (see details) 0125 Benjamin E. Reubinoff Hadassah Hebrew University Medical Center 06/16/2011 RNJ19; disease-specific mutation (see details) 0126 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011 RNJ20; disease-specific mutation (see details) 0127 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011 RNJ18; disease-specific mutation (see details) 0128 Reprogenetics, LLC Reprogenetics, LLC 06/16/2011 ESI-035 (see details) 0129 BioTime, Inc. BioTime, Inc. 08/18/2011 ESI-049 (see details) 0130 BioTime, Inc. BioTime, Inc. 08/18/2011 ESI-051 (see details) 0131 BioTime, Inc. BioTime, Inc. 08/18/2011 ESI-053 (see details) 0132 BioTime, Inc. BioTime, Inc. 08/18/2011 CSES5; abnormal karyotype (see details) 0133 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 09/27/2011 CSES6; abnormal karyotype (see details) 0134 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 09/27/2011 CSES18 (see details) 0135 Dhruv Sareen, Ph.D. Cedars-Sinai Medical Center 09/27/2011 HUES PGD 14; disease-specific mutation (see details) 0136 Eggan Lab Harvard University 10/11/2011 CA1 (see details) 0137 Andras Nagy Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011 CA2 (see details) 0138 Andras Nagy Mt Sinai Hosp-Samuel Lunenfeld Research Institute 12/12/2011 MEL-1 (see details) 0139 StemCore, Stem Cells Ltd University of Queensland 12/22/2011 MEL-2 (see details) 0140 StemCore, Stem Cells Ltd University of Queensland 12/22/2011 MEL-3 (see details) 0141 StemCore, Stem Cells Ltd University of Queensland 12/22/2011 MEL-4 (see details) 0142 StemCore, Stem Cells Ltd University of Queensland 12/22/2011 UCLA 7; disease-specific mutation/abnormal karyotype (see details) 0143 Steven Peckman University of California, Los Angeles 01/12/2012 UCLA 8 (see details) 0144 Steven Peckman University of California, Los Angeles 01/12/2012 UCLA 9 (see details) 0145 Steven Peckman University of California, Los Angeles 01/12/2012 UCLA 10 (see details) 0146 Steven Peckman University of California, Los Angeles 01/12/2012 UM4-6 (see details) 0147 Gary D. Smith, University of Michigan University of Michigan 02/02/2012 HUES PGD 1; disease-specific mutation (see details) 0148 Eggan Lab Harvard University 02/24/2012 HUES PGD 15; possible disease-specific mutation (see details) 0149 Eggan Lab Harvard University 02/24/2012 HUES PGD 16; disease-specific mutation (see details) 0150 Eggan Lab Harvard University 02/24/2012 GENEA002 (see details) 0151 Genea Biocells Genea Biocells 03/20/2012 GENEA048; abnormal karyotype (see details) 0152 Genea Biocells Genea Biocells 03/20/2012 UM11-1PGD; disease-specific mutation (see details) 0153 Gary D. Smith, University of Michigan University of Michigan 04/12/2012 UM9-1PGD; disease-specific mutation (see details) 0154 Gary D. Smith, University of Michigan University of Michigan 05/14/2012 UM38-2 PGD; disease-specific mutation (see details) 0155 Gary D. Smith, University of Michigan University of Michigan 05/14/2012 Elf1 (see details) 0156 University of Washington 05/15/2012 HUES 42 (see details) 0157 HSCI iPS Core Harvard University 05/31/2012 HUES 44 (see details) 0158 HSCI iPS Core Harvard University 05/31/2012 NMR-1 (see details) 0159 Rick A. Wetsel, Ph.D. University of Texas Hlth Sci Ctr Houston 05/31/2012 UM17-1 PGD; disease-specific mutation (see details) 0160 Gary D. Smith/University of Michigan University of Michigan 05/31/2012 UM15-4 PGD; disease-specific mutation (see details) 0161 University of Michigan, Gary D. Smith University of Michigan 05/31/2012 UM14-1 (see details) 0162 Gary D. Smith/University of Michigan University of Michigan 05/31/2012 UM14-2 (see details) 0163 Gary D. Smith/University of Michigan University of Michigan 05/31/2012 UM29-2 PGD; disease-specific mutation (see details) 0164 Gary D. Smith/University of Michigan University of Michigan 06/18/2012 UM29-3 PGD; disease-specific mutation (see details) 0165 Gary D. Smith/University of Michigan University of Michigan 06/18/2012 GENEA017; disease-specific mutation (see details) 0166 Genea Biocells Genea Biocells 06/20/2012 GENEA041; disease-specific mutation (see details) 0167 Genea Biocells Genea Biocells 06/20/2012 GENEA068; disease-specific mutation (see details) 0168 Genea Biocells Genea Biocells 06/20/2012 GENEA018; disease-specific mutation (see details) 0169 Genea Biocells Genea Biocells 06/20/2012 GENEA024; disease-specific mutation (see details) 0170 Genea Biocells Genea Biocells 06/20/2012 GENEA040; disease-specific mutation (see details) 0171 Genea Biocells Genea Biocells 06/20/2012 GENEA060; disease-specific mutation (see details) 0172 Genea Biocells Genea Biocells 06/20/2012 GENEA061; disease-specific mutation (see details) 0173 Genea Biocells Genea Biocells 06/20/2012 GENEA064; disease-specific mutation (see details) 0174 Genea Biocells Genea Biocells 06/20/2012 GENEA059; disease-specific mutation (see details) 0175 Genea Biocells Genea Biocells 07/09/2012 HUES 68 (see details) 0176 HSCI iPS Core Harvard University 07/09/2012 HUES 70 (see details) 0177 HSCI iPS Core Harvard University 07/09/2012 HUES 69 (see details) 0178 HSCI iPS Core Harvard University 08/07/2012 HUES PGD 10 (see details) 0179 Eggan Lab Harvard University 09/24/2012 GENEA046; disease-specific mutation (see details) 0180 Genea Biocells Genea Biocells 10/05/2012 GENEA069; disease-specific mutation (see details) 0181 Genea Biocells Genea Biocells 10/05/2012 GENEA070; disease-specific mutation (see details) 0182 Genea Biocells Genea Biocells 10/05/2012 GENEA049; disease-specific mutation (see details) 0183 Genea Biocells Genea Biocells 11/02/2012 GENEA050; disease-specific mutation (see details) 0184 Genea Biocells Genea Biocells 11/02/2012 UCLA 11 (see details) 0185 Steven Peckman University of California, Los Angeles 11/20/2012 UCLA 12 (see details) 0186 Steven Peckman University of California, Los Angeles 11/20/2012 GENEA062; disease-specific mutation (see details) 0187 Genea Biocells Genea Biocells 12/14/2012 GENEA063; disease-specific mutation (see details) 0188 Genea Biocells Genea Biocells 12/14/2012 GENEA066; disease-specific mutation (see details) 0189 Genea Biocells Genea Biocells 12/14/2012 GENEA067; disease-specific mutation (see details) 0190 Genea Biocells Genea Biocells 12/14/2012 GENEA071; disease-specific mutation (see details) 0191 Genea Biocells Genea Biocells 12/14/2012 GENEA072; disease-specific mutation (see details) 0192 Genea Biocells Genea Biocells 12/14/2012 GENEA073; disease-specific mutation (see details) 0193 Genea Biocells Genea Biocells 12/14/2012 GENEA074; disease-specific mutation (see details) 0194 Genea Biocells Genea Biocells 12/14/2012 HUES PGD 2; possible disease-specific mutation (see details) 0195 Eggan Lab Harvard University 12/14/2012 WA25 (see details) 0196 WiCell Research Institute WiCell Research Institute 12/14/2012 WA26 (see details) 0197 WiCell Research Institute WiCell Research Institute 12/14/2012 WA27 (see details) 0198 WiCell Research Institute WiCell Research Institute 12/14/2012 GENEA058; Disease-specific mutation (see details) 0199 Genea Biocells Genea Biocells 01/08/2013 GENEA065; Disease-specific mutation (see details) 0200 Genea Biocells Genea Biocells 01/08/2013 HS346 (see details) 0201 Karolinska Institute Karolinska Institute 03/18/2013 HS401 (see details) 0202 Karolinska Institute Karolinska Institute 03/18/2013 HS420 (see details) 0203 Karolinska Institute Karolinska Institute 03/18/2013 I3 (TE03) (see details) 0204 Technion R&D foundation Technion R&D Foundation 03/18/2013 I4 (TE04) (see details) 0205 Technion R&D foundation Technion R&D Foundation 03/18/2013 I6 (TE06) (see details) 0206 Technion R&D foundation Technion R&D Foundation 03/18/2013 HS799; disease-specific mutation (see details) 0207 Karolinska Institute Karolinska Institute 03/18/2013 UM57-1 PGD; disease-specific mutation (see details) 0208 Gary D. Smith/University of Michigan University of Michigan 03/26/2013 UM22-2 (see details) 0209 Gary D. Smith/University of Michigan University of Michigan 03/26/2013 CR-4 (see details) 0210 Rick A. Wetsel, Ph.D. University of Texas Hlth Sci Ctr at Houston 05/29/2013 WCMC-37; disease-specific mutation (see details) 0211 Weill Cornell Medical College- Nikica Zaninovic, PhD and Zev Rosenwaks, MD Joan & Sanford I. Weill Medical College of Cornell University 06/27/2013 KCL011 (see details) 0212 Dusko Ilic, King's College London King's College London 09/19/2013 KCL012; disease-specific mutation (see details) 0213 Dusko Ilic, King's College London King's College London 09/19/2013 KC013; disease-specific mutation (see details) 0214 Dusko Ilic, King's College London King's College London 09/19/2013 KCL015; disease-specific mutation (see details) 0215 Dusko Ilic, King's College London King's College London 09/19/2013 KCL016; disease-specific mutation (see details) 0216 Dusko Ilic, King's College London King's College London 09/19/2013 KCL017; disease-specific mutation (see details) 0217 Dusko Ilic, King's College London King's College London 09/19/2013 KCL018; disease-specific mutation (see details) 0218 Dusko Ilic, King's College London King's College London 09/19/2013 KCL021; disease-specific mutation (see details) 0219 Dusko Ilic, King's College London King's College London 09/19/2013 KCL024; disease-specific mutation (see details) 0220 Dusko Ilic, King's College London King's College London 09/19/2013 KCL025; disease-specific mutation (see details) 0221 Dusko Ilic, King's College London King's College London 09/19/2013 KCL026; disease-specific mutation (see details) 0222 Dusko Ilic, King's College London King's College London 09/19/2013 KCL027; disease-specific mutation (see details) 0223 Dusko Ilic, King's College London King's College London 09/19/2013 KCL028; disease-specific mutation (see details) 0224 Dusko Ilic, King's College London King's College London 09/19/2013 KCL029; disease-specific mutation (see details) 0225 Dusko Ilic, King's College London King's College London 09/19/2013 KCL030; disease-specific mutation (see details) 0226 Dusko Ilic, King's College London King's College London 09/19/2013 KCL035; disease-specific mutation (see details) 0227 Dusko Ilic, King's College London King's College London 09/19/2013 GENEA015 (see details) 0228 Genea Biocells Genea Biocells 09/30/2013 GENEA016 (see details) 0229 Genea Biocells Genea Biocells 09/30/2013 GENEA047 (see details) 0230 Genea Biocells Genea Biocells 09/30/2013 GENEA042 (see details) 0231 Genea Biocells Genea Biocells 09/30/2013 GENEA043 (see details) 0232 Genea Biocells Genea Biocells 09/30/2013 GENEA057 (see details) 0233 Genea Biocells Genea Biocells 09/30/2013 GENEA052 (see details) 0234 Genea Biocells Genea Biocells 09/30/2013 NYUES12 (see details) 0235 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 NYUES11; abnormal karyotype (see details) 0236 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 NYUES13 (see details) 0237 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 NYUES8 (see details) 0238 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 NYUES9 (see details) 0239 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 NYUES10 (see details) 0240 Christoph Hansis, MD, PhD New York University School of Medicine 12/23/2013 KCL036; disease-specific mutation (see details) 0241 Dusko Ilic, King's College London King's College London 12/23/2013 KCL042; disease-specific mutation (see details) 0242 Dusko Ilic, King's College London King's College London 12/23/2013 KCL043; disease-specific mutation (see details) 0243 Dusko Ilic, King's College London King's College London 12/23/2013 GENEA096; disease-specific mutations (see details) 0244 Genea Biocells Genea Biocells 01/29/2014 GENEA090; disease-specific mutations (see details) 0245 Genea Biocells Genea Biocells 01/29/2014 GENEA091; disease-specific mutations (see details) 0246 Genea Biocells Genea Biocells 01/29/2014 GENEA089; disease-specific mutations (see details) 0247 Genea Biocells Genea Biocells 01/29/2014 GENEA097; disease-specific mutations (see details) 0248 Genea Biocells Genea Biocells 01/29/2014 GENEA098; disease-specific mutations (see details) 0249 Genea Biocells Genea Biocells 01/29/2014 GENEA085 ; disease-specific mutation (see details) 0250 Genea Biocells Genea Biocells 01/29/2014 GENEA082 ; disease-specific mutation, abnormal karyotype (see details) 0251 Genea Biocells Genea Biocells 01/29/2014 GENEA078 ; disease-specific mutation (see details) 0252 Genea Biocells Genea Biocells 01/29/2014 GENEA079 ; disease-specific mutation (see details) 0253 Genea Biocells Genea Biocells 01/29/2014 GENEA080 ; disease-specific mutation (see details) 0254 Genea Biocells Genea Biocells 01/29/2014 GENEA081 ; disease-specific mutation (see details) 0255 Genea Biocells Genea Biocells 01/29/2014 GENEA083; disease-specific mutations, abnormal karyotype (see details) 0256 Genea Biocells Genea Biocells 01/29/2014 GENEA084 ; disease-specific mutation (see details) 0257 Genea Biocells Genea Biocells 01/29/2014 GENEA086 ; disease-specific mutation (see details) 0258 Genea Biocells Genea Biocells 01/29/2014 GENEA087 ; disease-specific mutation (see details) 0259 Genea Biocells Genea Biocells 01/29/2014 GENEA088 ; disease-specific mutation (see details) 0260 Genea Biocells Genea Biocells 01/29/2014 GENEA077; disease-specific mutation (see details) 0261 Genea Biocells Genea Biocells 01/29/2014 KCL023 (see details) 0262 Dusko Ilic, King's College London King's College London 03/25/2014 KCL031 (see details) 0263 Dusko Ilic, King's College London King's College London 03/25/2014 KCL022 (see details) 0264 Dusko Ilic, King's College London King's College London 03/25/2014 KCL038 (see details) 0265 Dusko Ilic, King's College London King's College London 03/25/2014 KCL032 (see details) 0266 Dusko Ilic, King's College London King's College London 03/25/2014 KCL033 (see details) 0267 Dusko Ilic, King's College London King's College London 03/25/2014 KCL034 (see details) 0268 Dusko Ilic, King's College London King's College London 03/25/2014 KCL037 (see details) 0269 Dusko Ilic, King's College London King's College London 03/25/2014 KCL019 (see details) 0270 Dusko Ilic, King's College London King's College London 03/25/2014 KCL020 (see details) 0271 Dusko Ilic, King's College London King's College London 03/25/2014 KCL040 (see details) 0272 Dusko Ilic, King's College London King's College London 03/25/2014 KCL041; abnormal karyotype/disease-specific mutation (see details) 0273 Dusko Ilic, King's College London King's College London 03/25/2014 KCL039 (see details) 0274 Dusko Ilic, King's College London King's College London 03/25/2014 UM59-2 PGD; disease-specific mutation (see details) 0275 Gary D. Smith/University of Michigan University of Michigan 04/09/2014 UM89-1 PGD; disease-specific mutation (see details) 0276 Gary D. Smith/University of Michigan University Of Michigan 04/09/2014 UM63-1 (see details) 0277 Gary D. Smith/University of Michigan University of Michigan 04/09/2014 UM77-2 (see details) 0278 Gary D. Smith / University of Michigan University of Michigan 04/09/2014 UM33-4 (see details) 0279 Gary D. Smith / University of Michigan University of Michigan 04/09/2014 HUES 75 (see details) 0280 Eggan Lab Harvard University 07/31/2014 HUES 71 (see details) 0281 Eggan Lab Harvard University 07/31/2014 HUES 72 (see details) 0282 Eggan Lab Harvard University 07/31/2014 HUES 73 (see details) 0283 Eggan Lab Harvard University 07/31/2014 CSC14 (see details) 0284 NeoStem, Inc. (Irvine) NeoStem, Inc. 09/18/2014 UM112-1 PGD; disease-specific mutation (see details) 0285 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM134-1 PGD; disease-specific mutation (see details) 0286 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM90-12 PGS; abnormal karyotype (see details) 0287 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM78-2 (see details) 0288 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM76-1 PGS; abnormal karyotype (see details) 0289 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM114-10 (see details) 0290 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM121-7 (see details) 0291 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UM139-2 PGD; disease-specific mutation (see details) 0292 Gary D. Smith / University of Michigan University of Michigan 09/29/2014 UCLA 13 (see details) 0293 Steven Peckman University of California, Los Angeles 10/16/2014 UCLA 14 (see details) 0294 Steven Peckman University of California, Los Angeles 10/16/2014 UCLA 15 (see details) 0295 Steven Peckman University of California, Los Angeles 10/16/2014 UCLA 16 (see details) 0296 Steven Peckman University of California, Los Angeles 10/16/2014 UCLA 17 (see details) 0297 Steven Peckman University of California, Los Angeles 10/16/2014 UCLA 18 (see details) 0298 Steven Peckman University of California, Los Angeles 10/16/2014 WIN-1 (see details) 0299 Whitehead Institute for Biomedical Research/Maisam Mitalipova Whitehead Institute for Biomedical Research 10/16/2014 WIN-2 (see details) 0300 Whitehead Institute for Biomedical Research/Maisam Mitalipova Whitehead Institute for Biomedical Research 10/16/2014 WIN-3 (see details) 0301 Whitehead Institute for Biomedical Research/Maisam Mitalipova Whitehead Institute for Biomedical Research 10/16/2014 WIN-4 (see details) 0302 Whitehead Institute for Biomedical Research/Maisam Mitalipova Whitehead Institute for Biomedical Research 10/16/2014 WIN-5 (see details) 0303 Whitehead Institute for Biomedical Research/Maisam Whitehead Institute for Biomedical Research 10/16/2014 HUES 74 (see details) 0304 Eggan Lab Harvard University 04/02/2015 UM25-2 (see details) 0305 Gary D. Smith / University of Michigan University of Michigan 04/02/2015 UM90-14 PGD; disease-specific mutation (see details) 0306 Gary D. Smith/ University of Michigan University of Michigan 04/02/2015 UM112-2 PGD; disease-specific mutation (see details) 0307 Gary D. Smith/ University of Michigan University of Michigan 04/02/2015

View original post here:
NIH Human Embryonic Stem Cell Registry - Research Using ...

Destructive Embryonic Stem Cell Research | Antiochian …

In this article, we will look at why the Orthodox Church has taken such a stand, how the Church has always stood uncompromisingly for the personhood of the human embryo, and what moral alternatives exist for stem cell research.

Destructive Embryonic Stem Cell Research

By Father Mark Hodges

THE STEM CELL DEBATE IS about the value of human life at its beginning. Stem cells are blank cells which can become all 210 different kinds of human tissue. Researchers hope that someday these cells could provide cures for all kinds of serious diseases, even repairing vital organs. We have stem cells throughout our bodies, but they are most abundant in human embryos. Retrieving embryonic stem cells, however, requires killing those human beings. A raging debate is going on in our nation now, over whether or not taxes should support killing human embryos in order to harvest their stem cells for experimentation.

Many influential groups have taken sides in the debate. You can guess where the pro-abortion groups stand. Drug and research companies also defend destructive embryonic stem cell research. Pro-life groups, of course, are against it. The Vatican condemned research using human embryos as gravely immoral, because removing cells kills an unborn child. U.S. Senator Sam Brownback debated on the floor of the senate: For the first time in our history, it is accept-able for medical researchers to kill one human being to help save another. Ultimately, what lies at the heart of this debate is our view of the human embryo. The central question in this debate is simple: Is the human embryo a person or a piece of property? If unborn persons are living beings, they have dignity and worth, and they deserve protection under the law from harm and destruction. If, however, unborn per-sons are a piece of property, then they can be destroyed with the con-sent of their owner.

The one, holy, catholic and apostolic Orthodox Church has spoken, too. The position of the Orthodox Church on embryonic stem cell research is, In light of the fact that Orthodox Christianity accepts the fact that human life begins at conception, the extraction of stem cells from embryos, which involves the willful taking of human life the embryo is human life and not just a clump of cells is considered morally and ethically wrong in every instance.

In this article, we will look at why the Orthodox Church has taken such a stand, how the Church has always stood uncompromisingly for the personhood of the human embryo, and what moral alternatives exist for stem cell research.

Legally, research on human embryos is allowed because of a faulty Supreme Court definition of personhood at viability (when a baby can lie out-side his/her mother) as worthy of state interest for legal protection. In fact, the whole pro-abortion argument hinges on the lie that there is such a thing as human life which is less than a person, hence unworthy of legal protection. Conversely, Orthodox Christians affirm the image of God from the beginning of human life, and we do not say at any time of development that one human being is of less value or less of a person than another human being.

Stem cells can be harvested from human embryos only by killing them, while the Church has always denounced any such killing and championed the sanctity of human life. The earliest extra-biblical document we have, The Didache, commands, Do not murder a child by abortion, and warns that the Way of Death is filled with people who are murderers of children and abortionists of Gods creatures (5:1-2). The Epistle of Barnabas, another very early document, was equally clear: You shall not destroy your conceptions before they are brought forth. Both call the embryo a child. St. Clement of Alexandria, in the third century, used Luke 1:41 (where John the Baptist leaped in Elizabeths womb) to prove that an embryo is a living person. He calls the earliest conceived embryos human beings who are given birth by Divine Providence, and he condemns those who use abortifacient medicines , causing the outright destruction, together with the fetus, of the whole human race.

Excerpt from:
Destructive Embryonic Stem Cell Research | Antiochian ...

What is Wrong With Embryonic Stem Cell Research?

Introduction

Are conservatives more concerned about a tiny clump of cells than the suffering of their fellow human beings? Is embryonic stem cell research (ESCR) really the cure-all for countless diseases? If you haven't kept up with the science involved in ESCR, this paper will jump-start your knowledge of the issues.

Embryonic stem cell research is a hot topic that seems to pit anti-abortion conservatives against pro-abortion liberals. The conservatives claim that there are better alternatives to embryonic stem cells, while the liberals claim that conservatives are blocking research that will provide cures to many tragic diseases. Much of the rhetoric is designed to muddy the waters to invoke emotional responses of those within each camp. This paper is designed to break through sound-bites and go the heart of the matter - what are the scientific issues that impact the question of stem cell research.

Much of what is promoted as being news is actually an oversimplification of the issues. Many news articles about stem cell research never distinguish between the kind of stem cell research that is being promoted. For example, the media often reports of breakthrough treatment for patients without mentioning that, in all cases, the source of stem cells is adult tissues. We know this to be true, because embryonic stem cells have never been used in human patients, and won't likely be used in the near future (see reasons, below).

Stem cells are classified as being pluripotent or multipotent. Stem cells that are pluripotent are capable of forming virtually all of the possible tissue types found in human beings. These stem cells can only be found in a certain stage (a blastocyst) in human embryos. Multipotent stem cells are partially differentiated, so that they can form a limited number of tissue types. Multipotent stem cells can be found in the fetus, in umbilical cord blood, and numerous adult tissues. A summary of this information can be found in the Table 1.

A list of the sources of stem cells, along with their advantages and disadvantages can be found in Table 2.

Although the controversy of stem cell research is only recent, research first began in the 1960's. The primary source of early human stem cells was adult bone marrow, the tissue that makes red and white blood cells. Since scientists realized that bone marrow was a good source of stem cells, early transplants were initiated in the early 1970's to treat diseases that involved the immune system (genetic immunodeficiencies and cancers of the immune system). Bone marrow-derived stem cell therapy has been extremely successful, with dozens of diseases being treated and cured through the use of these adult stem cells. However, because the donor tissue type must be closely matched to the patient, finding a compatible donor can be problematic. If you haven't already done so, you should become part of the Bone Marrow Registry.

With the advent of animal cloning, scientists had thought that patient-specific human cloning might provide cures without the tissue incompatibility problems usually associated with transplants. Specific stem cells, developed using clones genetically identical to the patient, would integrate optimally into the patient's body. Although ideal in theory, problems associated with human cloning have been quite formidable. After many years of trying to produce human clones, a South Korean group claimed to have done so in 2004,2 followed by a claim that they had produced patient-specific clones. However, subsequent questions revealed that all the research was fraudulent. Contrary to the original claims, the researchers failed to produce even one clone after over 2,000 attempts. Although a number of labs are working on producing human clones, none have succeeded - even after several years of additional attempts. At a cost of $1,000-$2,000 just to produce each human egg,3 therapeutic cloning would easily cost hundreds of thousands of dollars, if not more, for each patient. Therefore, these kinds of therapies would only be available to the wealthy, assuming the technical difficulties will eventually be eliminated.

Three separate groups of researchers showed recently that normal skin cells can be reprogrammed to an embryonic state in mice.4 The fact that these iPS cells were pluripotent was proved by producing fetuses derived entirely from these transformed skin cells. Just five months after the mouse study was published, the feat was repeated by two separate laboratories using human skin cells.5 The ability to produce embryonic stem cell-like lines from individual patients removes the possibility of tissues rejection and avoids the high costs and moral problems associated with cloned embryos. Dr. Shinya Yamanaka, one of the study leaders later commented, "When I saw the embryo, I suddenly realized there was such a small difference between it and my daughters... I thought, we cant keep destroying embryos for our research. There must be another way." The moral problem of destroying a human embryo encouraged Dr. Yamanaka to pursue a more ethical way to generate human stem cell lines. See the full report.

Stem cells have been promoted as a cure for numerous diseases in the popular press, although the reality of the science suggests otherwise. For example, claims that stem cells might cure Alzheimers disease are certainly untrue. According to Michael Shelanski, Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Columbia University Medical Center), I think the chance of doing repairs to Alzheimer's brains by putting in stem cells is small. Ronald D.G. McKay, National Institute of Neurological Disorders and Stroke says, To start with, people need a fairy tale.6 Stem cell research is widely promoted as a possible cure for type I and type II diabetes. However, these diseases involve the destruction of islet pancreatic cells by the patient's immune system. Even if tissue-compatible islet cells can be produced, transplanting them into a patient will be a very temporary cure, since the patient's immune system will attack the transplant in short order. So, a total cure for diabetes might have to involve a total immune compartment replacement (with its risks), in addition to an islet cell transplant. Parkinsons disease is another disease that is often mentioned as potentially curable through stem cell research. Proponents of ESCR cite studies in which embryonic stem cells produce dopamine in the brain of rats. However, only 50% of the rats had improvement of function and 25% developed brain tumors and died!7 A main problem for ESCR is that these stem cells spontaneously form tumors in virtually all studies that have been conducted to date. In addition, it seems that the number of dopamine-producing neurons declined over time, suggesting that the cure might be just temporary.8

Read more from the original source:
What is Wrong With Embryonic Stem Cell Research?

Embryonic stem cell – Science Daily

Embryonic stem cells (ESCs) are stem cells derived from the undifferentiated inner mass cells of a human embryo.

Embryonic stem cells are pluripotent, meaning they are able to grow (i.e. differentiate) into all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm.

In other words, they can develop into each of the more than 200 cell types of the adult body as long as they are specified to do so.

Embryonic stem cells are distinguished by two distinctive properties: their pluripotency, and their ability to replicate indefinitely.

ES cells are pluripotent, that is, they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm.

These include each of the more than 220 cell types in the adult body.

Pluripotency distinguishes embryonic stem cells from adult stem cells found in adults; while embryonic stem cells can generate all cell types in the body, adult stem cells are multipotent and can produce only a limited number of cell types.

Additionally, under defined conditions, embryonic stem cells are capable of propagating themselves indefinitely.

This allows embryonic stem cells to be employed as useful tools for both research and regenerative medicine, because they can produce limitless numbers of themselves for continued research or clinical use.

Because of their plasticity and potentially unlimited capacity for self-renewal, ES cell therapies have been proposed for regenerative medicine and tissue replacement after injury or disease.

Continued here:

Embryonic stem cell - Science Daily

What are embryonic stem cells? [Stem Cell Information]

Introduction: What are stem cells, and why are they important? What are the unique properties of all stem cells? What are embryonic stem cells? What are adult stem cells? What are the similarities and differences between embryonic and adult stem cells? What are induced pluripotent stem cells? What are the potential uses of human stem cells and the obstacles that must be overcome before these potential uses will be realized? Where can I get more information? A. What stages of early embryonic development are important for generating embryonic stem cells?

Embryonic stem cells, as their name suggests, are derived from embryos. Most embryonic stem cells are derived from embryos that develop from eggs that have been fertilized in vitroin an in vitro fertilization clinicand then donated for research purposes with informed consent of the donors. They are not derived from eggs fertilized in a woman's body.

Growing cells in the laboratory is known as cell culture. Human embryonic stem cells (hESCs) aregenerated by transferringcells from a preimplantation-stage embryointo a plastic laboratory culture dish that contains a nutrient broth known as culture medium. The cells divide and spread over the surface of the dish. In the original protocol, the inner surface of the culture dish was coated with mouse embryonic skin cellsspecially treated so they will not divide. This coating layer of cells is called a feeder layer. The mouse cells in the bottom of the culture dish provide the cells a sticky surface to which they can attach. Also, the feeder cells release nutrients into the culture medium. Researchers have nowdevised ways to grow embryonic stem cells without mouse feeder cells. This is a significant scientific advance because of the risk that viruses or other macromolecules in the mouse cells may be transmitted to the human cells.

The process of generating an embryonic stem cell line is somewhat inefficient, so lines are not produced each time cells from the preimplantation-stage embryo are placed into a culture dish. However, if the plated cells survive, divide and multiply enough to crowd the dish, they are removed gently and plated into several fresh culture dishes. The process of re-plating or subculturing the cells is repeated many times and for many months. Each cycle of subculturing the cells is referred to as a passage. Once the cell line is established, the original cells yield millions of embryonic stem cells. Embryonic stem cells that have proliferated in cell culture for for a prolonged period of time without differentiating, and are pluripotentare referred to as an embryonic stem cell line. At any stage in the process, batches of cells can be frozen and shipped to other laboratories for further culture and experimentation.

At various points during the process of generating embryonic stem cell lines, scientists test the cells to see whether they exhibit the fundamental properties that make them embryonic stem cells. This process is called characterization.

Scientists who study human embryonic stem cells have not yet agreed on a standard battery of tests that measure the cells' fundamental properties. However, laboratories that grow human embryonic stem cell lines use several kinds of tests, including:

As long as the embryonic stem cells in culture are grown under appropriate conditions, they can remain undifferentiated (unspecialized). But if cells are allowed to clump together to form embryoid bodies, they begin to differentiate spontaneously. They can form muscle cells, nerve cells, and many other cell types. Although spontaneous differentiation is a good indication that a culture of embryonic stem cells is healthy, it is not an efficient way to produce cultures of specific cell types.

So, to generate cultures of specific types of differentiated cellsheart muscle cells, blood cells, or nerve cells, for examplescientists try to control the differentiation of embryonic stem cells. They change the chemical composition of the culture medium, alter the surface of the culture dish, or modify the cells by inserting specific genes. Through years of experimentation, scientists have established some basic protocols or "recipes" for the directed differentiation of embryonic stem cells into some specific cell types (Figure 1). (For additional examples of directed differentiation of embryonic stem cells, refer to the NIH stem cell report available at http://stemcells.nih.gov/info/scireport/pages/2006report.aspx.)

Figure 1. Directed differentiation of mouse embryonic stem cells. Click here for larger image. ( 2008 Terese Winslow)

Link:

What are embryonic stem cells? [Stem Cell Information]

Stem Cell Research Article, Embryonic Cells Information …

In the beginning, one cell becomes two, and two become four. Being fruitful, they multiply into a ball of many cells, a shimmering sphere of human potential. Scientists have long dreamed of plucking those naive cells from a young human embryo and coaxing them to perform, in sterile isolation, the everyday miracle they perform in wombs: transforming into all the 200 or so kinds of cells that constitute a human body. Liver cells. Brain cells. Skin, bone, and nerve.

The dream is to launch a medical revolution in which ailing organs and tissues might be repairednot with crude mechanical devices like insulin pumps and titanium joints but with living, homegrown replacements. It would be the dawn of a new era of regenerative medicine, one of the holy grails of modern biology.

Revolutions, alas, are almost always messy. So when James Thomson, a soft-spoken scientist at the University of Wisconsin in Madison, reported in November 1998 that he had succeeded in removing cells from spare embryos at fertility clinics and establishing the world's first human embryonic stem cell line, he and other scientists got a lot more than they bargained for. It was the kind of discovery that under most circumstances would have blossomed into a major federal research enterprise. Instead the discovery was quickly engulfed in the turbulent waters of religion and politics. In church pews, congressional hearing rooms, and finally the Oval Office, people wanted to know: Where were the needed embryos going to come from, and how many would have to be destroyed to treat the millions of patients who might be helped? Before long, countries around the world were embroiled in the debate.

Most alarmed have been people who see embryos as fully vested, vulnerable members of society, and who decry the harvesting of cells from embryos as akin to cannibalism. They warn of a brave new world of "embryo farms" and "cloning mills" for the cultivation of human spare parts. And they argue that scientists can achieve the same results using adult stem cells immature cells found in bone marrow and other organs in adult human beings, as well as in umbilical cords normally discarded at birth.

Advocates counter that adult stem cells, useful as they may be for some diseases, have thus far proved incapable of producing the full range of cell types that embryonic stem cells can. They point out that fertility clinic freezers worldwide are bulging with thousands of unwanted embryos slated for disposal. Those embryos are each smaller than the period at the end of this sentence. They have no identifying features or hints of a nervous system. If parents agree to donate them, supporters say, it would be unethical not to do so in the quest to cure people of disease.

Few question the medical promise of embryonic stem cells. Consider the biggest United States killer of all: heart disease. Embryonic stem cells can be trained to grow into heart muscle cells that, even in a laboratory dish, clump together and pulse in spooky unison. And when those heart cells have been injected into mice and pigs with heart disease, they've filled in for injured or dead cells and sped recovery. Similar studies have suggested stem cells' potential for conditions such as diabetes and spinal cord injury.

Critics point to worrisome animal research showing that embryonic stem cells sometimes grow into tumors or morph into unwanted kinds of tissuespossibly forming, for example, dangerous bits of bone in those hearts they are supposedly repairing. But supporters respond that such problems are rare and a lot has recently been learned about how to prevent them.

The arguments go back and forth, but policymakers and governments aren't waiting for answers. Some countries, such as Germany, worried about a slippery slope toward unethical human experimentation, have already prohibited some types of stem cell research. Others, like the U.S., have imposed severe limits on government funding but have left the private sector to do what it wants. Still others, such as the U.K., China, Korea, and Singapore, have set out to become the epicenters of stem cell research, providing money as well as ethical oversight to encourage the field within carefully drawn bounds.

In such varied political climates, scientists around the globe are racing to see which techniques will produce treatments soonest. Their approaches vary, but on one point, all seem to agree: How humanity handles its control over the mysteries of embryo development will say a lot about who we are and what we're becoming.

For more than halfof his seven years, Cedric Seldon has been fighting leukemia. Now having run out of options, he is about to become a biomedical pioneerone of about 600 Americans last year to be treated with an umbilical cord blood transplant.

Read more:

Stem Cell Research Article, Embryonic Cells Information ...

Practical Problems with Embryonic Stem Cells

While some researchers still claim that embryonic stem cells (ESCs) offer the best hope for treating many debilitating diseases, there is now a great deal of evidence contrary to that theory. Use of stem cells obtained by destroying human embryos is not only unethical but presents many practical obstacles as well.

"Major roadblocks remain before human embryonic stem cells could be transplanted into humans to cure diseases or replace injured body parts, a research pioneer said Thursday night. University of Wisconsin scientist James Thomson said obstacles include learning how to grow the cells into all types of organs and tissue and then making sure cancer and other defects are not introduced during the transplantation. 'I don't want to sound too pessimistic because this is all doable, but it's going to be very hard,' Thomson told the Wisconsin Newspaper Association's annual convention at the Kalahari Resort in this Wisconsin Dells town. 'Ultimately, those transplation therapies should work but it's likely to take a long time.'....Thomson cautioned such breakthroughs are likely decades away."

-Associated Press reporter Ryan J. Foley "Stem cell pioneer warns of roadblocks before cures," San Jose Mercury News Online, posted on Feb. 8, 2007, http://www.mercurynews.com/mld/mercurynews/16656570.htm

***

"Although embryonic stem cells have the broadest differentiation potential, their use for cellular therapeutics is excluded for several reasons: the uncontrollable development of teratomas in a syngeneic transplantation model, imprinting-related developmental abnormalities, and ethical issues."

-Gesine Kgler et al., "A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential," Journal of Experimental Medicine, Vol. 200, No. 2 (July 19, 2004), p. 123.

***

From a major foundation promoting research in pancreatic islet cells and other avenues for curing juvenile diabetes:

"Is the use of embryonic stem cells close to being used to provide a supply of islet cells for transplantation into humans?

"No. The field of embryonic stem cells faces enormous hurtles to overcome before these cells can be used in humans. The two key challenges to overcome are making the stem cells differentiate into specific viable cells consistently, and controlling against unchecked cell division once transplanted. Solid data of stable, functioning islet cells from embryonic stems cells in animals has not been seen."

Here is the original post:

Practical Problems with Embryonic Stem Cells